Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastatic Brain Tumor
- Sponsor
- Swedish Medical Center
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS
- Last Updated
- 12 years ago
Overview
Brief Summary
This registry study will evaluate patients with metastatic brain tumors undergoing, or having undergone, stereotactic radiosurgery (SRS) at Swedish Medical Center. Clinical outcomes will be evaluated at the 3, 6 and 12-month time points. Clinical data, SRS treatment data, and imaging data (including anatomic and advanced imaging sequences obtained prior to and serially following SRS) will be archived in an online informatics platform, specifically a metastatic brain tumor registry known as the Comprehensive Neuro-oncology Data Repository for Metastatic Tumors (CONDR - Mets).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients (\>18 yo) with a pathological diagnosis of metastatic brain cancer
- •Participants must have \>4 tumors felt to require stereotactic radiosurgery
- •Karnofsky scale of \> 70 at the time of initial treatment
- •Age \< 80
Exclusion Criteria
- •Karnofsky scale \<70
- •Age \> 80
- •Inability to undergo MR imaging studies
Outcomes
Primary Outcomes
Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS
Time Frame: At the time of SRS
Quantitative measures of tumor number will be performed for each subject at the time of SRS
Time Frame: At the time of SRS
Overall survival will be measured for each subject (in weeks from SRS to death)
Time Frame: Post-SRS
Secondary Outcomes
- Measures of ADC, rCBV, MTT and ktrans will be performed for each treated tumor at treatment and at 6 months following SRS(6 months post SRS)
- Time to progression (in weeks) will be measured for each treated tumor(Post-SRS)
- Diagnosis of progression or radiation necrosis (made on clinical reflection at study's end) will be determined for tumors where diagnosis is in question at 6 and 12 months after SRS(12 months post-SRS)